Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases.
Francesco BonellaVincent CottinClaudia ValenzuelaMarlies WijsenbeekFlorian VossKlaus B RohrSusanne StowasserToby M MaherPublished in: Advances in therapy (2022)
A meta-analysis of data from four placebo-controlled trials demonstrated that nintedanib approximately halved the rate of decline in FVC over 52 weeks across subjects with different forms of pulmonary fibrosis, with no evidence of heterogeneity in its relative treatment effect across patient populations.
Keyphrases
- pulmonary fibrosis
- idiopathic pulmonary fibrosis
- systematic review
- placebo controlled
- interstitial lung disease
- case report
- meta analyses
- double blind
- single cell
- electronic health record
- big data
- randomized controlled trial
- rheumatoid arthritis
- machine learning
- case control
- replacement therapy
- phase ii
- data analysis